The past week delivered a coordinated sequence of moves that, taken together, quietly reset expectations for how global systems will price, approve, pay for, and ultimately adopt innovation in 2026. What distinguished this week was not the volume of news but its consistency: across borders and agencies, decision-makers leaned into a shared posture, broadened access … Read more
The Reimbursement Landscape Recalibrates As we pause for the Thanksgiving holiday, a sincere thank-you to our readers and partners for your continued engagement. This week’s update reflects a period of meaningful policymaking momentum across major global agencies. Across the U.S., UK, France, Canada and Thailand, agencies delivered firm, directional decisions that shape how hospitals, clinics … Read more
This week showcased a widening split in global healthcare strategy: payers strengthened cost discipline and evidence demands, while industry advanced AI platforms, precision oncology, and cloud-native diagnostics.
The Week’s Biggest Shifts in Payer Strategy This week’s policy and access landscape was defined by a sweeping overhaul of U.S. Medicaid drug pricing and a widening push toward value-driven reimbursement models. CMS’ newly announced GENEROUS model, paired with Most Favored Nation (MFN) pricing agreements for GLP-1s, marks a structural shift that will reshape affordability … Read more
Global market access shifts: HTA speed, UK pricing, digital disruption.
Healthcare deal spotlight September 1 to 7, 2025